The text starts here.

Production and Logistics (Demand Chain Systems)

Establishing a Global, Patient-Oriented Production System

Eisai's Transformation from a Site-Based Production Model,
to a Global Structure Organized by Product Family

“The quality of every single tablet, capsule, and ampule that we produce is integral to the life of the patient.”

This is Eisai's general policy on product quality, with each employee keenly aware that every drug manufactured by us directly affects patients' lives. It is this conviction that is reflected in every aspect of our production activities and we believe that as long as there are people around the world in need of medicine, there exists a mission and a responsibility to continue to assure the stable supply of high-quality pharmaceutical products. To achieve this, the Eisai Group consistently strives for high quality through its introduction of a robust management system that oversees all processes from drug substance and formulation research to production and distribution.
With the aim of providing a stable supply of high-quality products at affordable prices worldwide, including in emerging and developing countries, in October 2012 we transitioned from a production structure that emphasized the optimization of each production site to a global structure that implements end-to-end production activities from the procurement of raw materials to production, packaging and shipment in each product lineup.

Under this new system, we aim to increase patient satisfaction by accurately identifying the needs of patients in each product area and optimizing management at every stage, including the procurement of raw materials, manufacturing processes, quality control, and logistics and market supply. Through the development of a unique, global demand chain* based on the belief that “everything we do should reflect the needs of patients, their families, and customers,” we continue to work toward ensuring the stable supply of high-quality medicines throughout the world.

Shift from a “Production structure emphasizing optimization of each production site” to a “Global production structure that implements end-to-end production in each product lineup”

*What is a demand chain?
Under the concept of the “demand chain,” besides the production and supply of products, the goal is to build systems to ensure that production activities and product improvements are actively geared to meeting the demands of patients.

A Global Structure to Ensure the Stable Supply of Medicines

The system that we have introduced enables us to distribute products on a global scale from multiple sites while also ensuring a stable supply of high-quality medicines to people around the world in times of emergency.

■Manufacturing Sites Worldwide

Back to Top

Japan Manufacturing Sites

Kawashima Plant

Location Kawashima-Takehaya, Kakamigahara, Gifu
Site Area 466,474m2
Year Completed 1966
Characteristics Manufactures prescription drugs (including film-coated tablets, fine granules and capsules) and vitamin E as an active pharmaceutical ingredient (API) for domestic and overseas supply. Its manufacturing facilities have introduced an automated boxing system, with advanced packaging lines equipped with automated robotic arms and automated conveyor systems.

Kashima Plant

Location Sunayama, Kamisu, Ibaraki
Site Area 239,664m2
Year Completed 1984
Characteristics Global production center for APIs. Performs dual functions of industrial research and API production as well as inspection of API production processes with the aim of commercial production at earlier stages of drug development. Continues to achieve in product quality improvement, stable supply, and environmental conservation through efficiency management changes to its manufacturing processes.

Sannova Co., Ltd.

Location Serada, Ota, Gunma
Site Area 57,885m2
Year Completed 1989
Characteristics Manufactures prescription drugs, generic drugs marketed by Elmed Eisai, over-the-counter (OTC) drugs, quasi-drugs and cosmetics. Equipped to handle production of a wide range of formulations, including fine granules, powders, tablets (including sugar-coated, film-coated, and orally disintegrating tablets), solutions, ointments, creams and lotions.

* The business operations at the Misato Plant were transferred to Bushu Pharmaceuticals Ltd. as of March 31, 2014. With regard to parenteral formulations production, however, Eisai leases back the manufacturing facility and continues production.

Back to Top

Global Manufacturing Sites

Hatfield Plant (U.K.)

Location European Knowledge Centre, Hatfield, Hertfordshire, U.K.
Site Area 60,000m2
Year Completed 2009
Characteristics Having both packaging and oral solid dose manufacturing capabilities, the plant especially excels in handling packaging of low-volume multilingual products in Europe, where there is a particularly high linguistic diversity.
With regard to global products such as Halaven, Lenvima and Fycompa, the plant functions as a global production center, having commenced supply to countries in the Middle East, Africa, the Americas and Asia in addition to Europe.

Suzhou Factory (China)

Location Suzhou, Jiangsu, China
Site Area 25,171m2
Year Completed 1998
Characteristics Formulation manufacturing hub mainly responsible for handling production and packaging of prescription drugs for the Chinese market. To further ensure the stable supply and improve manufacturing efficiency, a Parenteral Formulation facility was built within the Suzhou Industrial Park. The decision was also made to build a new oral solid dose production facility within the same industrial park.

Vizag Plant (India)

Location Vizag, Andhra Pradesh, India
Site Area 200,000m2
Year Completed 2009
Characteristics Handles dual functions of API production and research into formulation production and APIs. Jointly responsible for Eisai's global API supply and serves as a supply center not only for emerging economies and the developing world but also developed countries, including Japan. In addition, the plant carries out a key role in Eisai's efforts to realize affordable pricing, and began production of antifilariasis medicine in August 2013 to provide at price zero to the World Health Organization (WHO) as a part of these efforts.

Bogor Factory (Indonesia)

Location Bogor, West Java, Indonesia
Site Area 30,000m2
Year Completed 1987
Characteristics Manufacturing site in charge of production and packaging of prescription drugs. There are currently plans to expand the market beyond Indonesia to include all the ASEAN countries in the future.

Baltimore Plant (U.S.)

Location Baltimore, Maryland, U.S.
Site Area 8,455m2 (Gliadel Manufacturing area 1,840m2)
Year Completed 1995
Characteristics The plant is responsible for the global supply of Gliadel Wafer, a biodegradable implant used during surgery for the treatment of brain cancer. The plant has received manufacturing approval from various countries worldwide, including Japan, the U.S. and EU member states.

* The business operations at the North Carolina Plant (U.S.) were transferred to Biogen Inc. as of August 25, 2015.

Back to Top